Recent Analysts’ Ratings Changes for Dyne Therapeutics (DYN)

Dyne Therapeutics (NASDAQ: DYN) has recently received a number of price target changes and ratings updates:

• 1/24/2025 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim.
• 1/14/2025 – Dyne Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $45.00 price target on the stock.
• 1/10/2025 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock.
• 1/10/2025 – Dyne Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
• 12/13/2024 – Dyne Therapeutics is now covered by analysts at Robert W. Baird. They set an “outperform” rating and a $46.00 price target on the stock.
• 12/12/2024 – Dyne Therapeutics was upgraded by analysts at Baird R W to a “strong-buy” rating.
• 12/12/2024 – Dyne Therapeutics was upgraded by analysts at Raymond James to a “strong-buy” rating.

Dyne Therapeutics Trading Up 0.6 %

DYN stock opened at $13.54 on Thursday. Dyne Therapeutics, Inc. has a 1-year low of $13.23 and a 1-year high of $47.45. The stock has a market cap of $1.38 billion, a P/E ratio of -3.80 and a beta of 1.16. The stock’s fifty day simple moving average is $23.06 and its two-hundred day simple moving average is $32.02.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Oxana Beskrovnaya sold 2,334 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now owns 201,685 shares of the company’s stock, valued at approximately $5,671,382.20. This represents a 1.14 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jason P. Rhodes sold 782 shares of the firm’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total value of $25,884.20. Following the transaction, the director now directly owns 15,962 shares in the company, valued at $528,342.20. This trade represents a 4.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,071 shares of company stock worth $606,476 over the last ninety days. 20.77% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Dyne Therapeutics

A number of large investors have recently bought and sold shares of DYN. AQR Capital Management LLC increased its stake in shares of Dyne Therapeutics by 4.3% in the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after buying an additional 352 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Dyne Therapeutics by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock valued at $123,000 after acquiring an additional 709 shares during the period. KBC Group NV raised its stake in shares of Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after acquiring an additional 751 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Dyne Therapeutics by 39.9% during the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after purchasing an additional 796 shares during the period. Finally, Quantbot Technologies LP bought a new stake in shares of Dyne Therapeutics in the third quarter worth about $34,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.